Observational studyThe oncologist2026
A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2- breast cancer in China.
Quchang Ouyang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it